Facebook Linkedin RSS Twitter Youtube
Home 2024

Regeneron

StockWatch: Insmed Shares Leap 150%, as Analysts See Next Blockbuster
Drug Discovery

StockWatch: Insmed Shares Leap 150%, as Analysts See Next Blockbuster

ASGCT 2024: Mammoth Sizes Up Genome Editing Opportunities
Genome Editing

ASGCT 2024: Mammoth Sizes Up Genome Editing Opportunities

Regeneron, Mammoth Launch In Vivo CRISPR Gene Editing Collaboration
GEN Edge

Regeneron, Mammoth Launch In Vivo CRISPR Gene Editing Collaboration

StockWatch: Regeneron Shares Dip as DOJ Alleges Fraudulent Price Reporting
Drug Discovery

StockWatch: Regeneron Shares Dip as DOJ Alleges Fraudulent Price Reporting

With $170M, BioAge Joins Lilly in Oral, Muscle Preserving Obesity Treatment
Drug Discovery

With $170M, BioAge Joins Lilly in Oral, Muscle Preserving Obesity Treatment

2seventy Sells Cell Therapy Operations to Regeneron, in Latest Restructuring
Cancer

2seventy Sells Cell Therapy Operations to Regeneron, in Latest Restructuring

StockWatch: Regeneron’s All Ears for Hearing Loss Drug Developer
Drug Discovery

StockWatch: Regeneron’s All Ears for Hearing Loss Drug Developer

Effective IoT Infrastructure Critical for Digital Drug Firms
Bioprocessing

Effective IoT Infrastructure Critical for Digital Drug Firms

Top 25 Biotech Companies of 2023
A-Lists

Top 25 Biotech Companies of 2023

Molecular Scissors Are Making the Cut … in Clinical Trials
Genome Editing

Molecular Scissors Are Making the Cut … in Clinical Trials

123...12Page 1 of 12
Copyright © 2024 Genetic Engineering & Biotechnology News. All Rights Reserved.